Atherosclerosis Reversal: Current Evidence on Plaque Regression and Stabilization

I. Understanding Atherosclerosis and Its Reversal

A. Atherosclerosis: Definition and Pathophysiology

Atherosclerosis is fundamentally characterized by the progressive accumulation of lipids (such as cholesterol), inflammatory cells, smooth muscle cells, and extracellular matrix components within the intimal layer of medium and large arteries. This buildup forms distinct lesions known as atherosclerotic plaques or atheromas.¹ This process leads to the thickening and hardening of the arterial walls, a condition referred to as arteriosclerosis, which narrows the arterial lumen, impedes blood flow, and increases vessel stiffness.³ Atherosclerosis is a systemic disease, potentially affecting arterial beds throughout the body, including the coronary, carotid, cerebral, peripheral (limbs), and renal arteries.³ Its clinical consequences, such as myocardial infarction (MI), stroke, and peripheral artery disease (PAD), represent the leading causes of morbidity and mortality globally.⁵

The pathophysiology of atherosclerosis is a complex, multi-stage process:

1. Initiation – Endothelial Dysfunction: The process often begins in childhood or adolescence ³ with damage or dysfunction of the endothelium, the single layer of cells lining the arteries. This dysfunction is triggered by various cardiovascular risk factors, including hypertension, dyslipidemia (particularly elevated low-density lipoprotein cholesterol, LDL-C), hyperglycemia/diabetes mellitus, cigarette smoking, and chronic inflammation.³ Endothelial dysfunction is characterized by reduced bioavailability of nitric oxide (NO), a key vasodilator and anti-inflammatory molecule, and increased oxidative stress.⁹ This impaired endothelial function increases permeability and promotes the expression of adhesion molecules.
2. Lipid Accumulation and Modification: Increased endothelial permeability facilitates the entry and retention of LDL particles and other apolipoprotein B (apoB)-containing lipoproteins within the subendothelial space (intima).⁷ Once trapped in the intima, these lipoproteins undergo modifications, most notably oxidation (forming oxidized LDL or oxLDL), which renders them highly pro-inflammatory and atherogenic.⁷
3. Inflammation and Immune Response: Endothelial activation leads to the upregulation of adhesion molecules like vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and selectins. These molecules recruit circulating leukocytes, primarily monocytes and T-lymphocytes, to the site of injury.⁷ Monocytes migrate into the intima, differentiate into macrophages, and avidly take up modified lipoproteins via scavenger receptors (e.g., CD36), transforming into lipid-laden “foam cells”.⁷ This accumulation of foam cells forms the earliest visible lesion, the fatty streak.⁹ This process is orchestrated by a complex network of pro-inflammatory cytokines (e.g., tumor necrosis factor-alpha, interleukin-1 [IL-1], IL-6) and chemokines (e.g., monocyte chemoattractant protein-1 [MCP-1]), involving signaling pathways such as nuclear factor-kappa B (NF-κB).⁹ The contemporary understanding of atherosclerosis emphasizes its nature as a chronic inflammatory disease, where both innate and adaptive immune responses play critical roles.⁹ This paradigm shift from viewing it solely as a lipid storage disease underscores the importance of inflammation as a therapeutic target. Emerging concepts also implicate immune checkpoints and clonal hematopoiesis of indeterminate potential (CHIP) in modulating atherosclerotic risk.²⁰
4. Plaque Progression and Maturation: Vascular smooth muscle cells (VSMCs) migrate from the media layer into the intima, where they proliferate and synthesize extracellular matrix components, including collagen.⁹ This process contributes to the formation of a fibrous cap overlying the lipid core. Continued accumulation of lipids, inflammatory cells, cellular debris from apoptotic cells, and extracellular matrix leads to the growth and evolution of the plaque into a more complex lesion.⁷ Advanced plaques often develop a central lipid-rich necrotic core (LRNC), containing cholesterol crystals, dead cells, and debris.⁷
5. Complications – Plaque Rupture/Erosion and Thrombosis: The clinical manifestations of atherosclerosis often arise from acute thrombotic events triggered by plaque disruption. Plaques deemed “vulnerable” or “high-risk” are prone to rupture or erosion.¹ Vulnerable plaques typically possess specific morphological characteristics, including a thin fibrous cap (<65 μm), a large LRNC, marked inflammation (e.g., dense macrophage infiltration), positive arterial remodeling (outward bulging of the vessel wall), and microcalcifications (spotty calcification).⁷ Rupture of the thin fibrous cap or erosion of the endothelial surface exposes the highly thrombogenic contents of the plaque (like tissue factor within the necrotic core) to the bloodstream, initiating platelet aggregation and coagulation cascade activation, leading to thrombus formation.¹ This thrombus can partially or completely occlude the artery, causing acute clinical events such as acute coronary syndromes (ACS, including unstable angina and MI), ischemic stroke, or acute limb ischemia.²

Atherosclerosis often remains asymptomatic for decades, with symptoms typically manifesting only when plaque burden leads to significant stenosis (often >70% luminal narrowing) limiting blood flow during increased demand, or when acute plaque disruption occurs.³ The specific symptoms depend on the arterial territory affected: coronary artery involvement may cause angina pectoris or MI ²; carotid artery disease can lead to transient ischemic attack (TIA) or stroke ³; peripheral artery disease manifests as intermittent claudication or critical limb ischemia ³; and renal artery stenosis can cause hypertension or kidney failure.³

Established risk factors contributing to atherosclerosis include modifiable factors such as dyslipidemia (high LDL-C, high triglycerides, low HDL-C), hypertension, cigarette smoking, diabetes mellitus, obesity, physical inactivity, and unhealthy dietary patterns ², alongside non-modifiable factors like advancing age, male sex, family history of premature CVD, and certain ethnicities.³ Emerging risk factors gaining attention include chronic inflammation from various sources, air pollution, disturbed sleep, environmental stress, and alterations in the gut microbiome.¹⁹

B. The Concept of Plaque Regression and Stabilization

The term “atherosclerosis reversal” is frequently used but lacks precise definition in clinical science. More accurate and meaningful terms are plaque regression, which refers to a measurable reduction in plaque size or volume, and plaque stabilization, which describes compositional changes within the plaque that render it less prone to rupture and subsequent thrombosis.¹⁸ While halting the progression of atherosclerosis is a primary goal of therapy, achieving significant regression, particularly of advanced, calcified lesions, remains challenging.¹⁸ For many therapeutic interventions, plaque stabilization may represent a more readily achievable and clinically impactful outcome than substantial volume reduction.²⁹

The processes underlying plaque regression and stabilization are complex and not merely a simple reversal of plaque formation.¹⁸ Key biological mechanisms involved include:

1. Lipid Depletion: A critical step involves reducing the lipid content of the plaque, particularly within the LRNC. This is achieved primarily by lowering circulating levels of atherogenic lipoproteins (mainly LDL-C) to reduce their influx into the arterial wall.⁴⁸ Simultaneously, enhancing cholesterol efflux from plaque macrophages back into the circulation (Reverse Cholesterol Transport, RCT) is crucial.¹⁸ High-density lipoprotein (HDL) particles play a key role as acceptors of cholesterol effluxed from macrophages via transporters like ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1).¹⁸ Therapeutic strategies aim to shift the lipid balance within macrophages towards efflux ¹⁸ and enhance hepatic clearance of lipoproteins.¹⁸
2. Resolution of Inflammation: Atherosclerosis is driven by chronic inflammation. Stabilization and regression involve reducing the infiltration and activity of inflammatory cells (macrophages, T-lymphocytes) within the plaque.¹³ This includes decreasing the production of pro-inflammatory cytokines and matrix-degrading enzymes (like matrix metalloproteinases, MMPs) that weaken the fibrous cap.¹³ Anti-inflammatory therapies specifically target these pathways.²²
3. Fibrous Cap Thickening: VSMCs play a crucial role in synthesizing collagen and other extracellular matrix proteins that form the fibrous cap.¹³ Therapeutic interventions that promote VSMC survival and synthetic function can lead to thickening and strengthening of the fibrous cap, making the plaque more resistant to rupture.¹³
4. Necrotic Core Reduction: The LRNC is a major determinant of plaque vulnerability. Effective clearance of apoptotic cells (efferocytosis) and lipid debris by macrophages, coupled with reduced lipid influx and inflammation, can lead to a reduction in the size of the necrotic core.¹³
5. Changes in Calcification: Vascular calcification is a complex process associated with advanced atherosclerosis. While extensive, bulky calcification contributes to arterial stiffness, certain patterns of calcification are observed during plaque stabilization. Therapies like statins may promote an increase in dense calcium volume or potentially facilitate the transition from unstable microcalcifications to more stable, sheet-like calcification, concurrent with lipid core reduction.¹³ The role of Vitamin K2 in regulating vascular calcification through the activation of Matrix Gla Protein (MGP) is an area of active investigation, with potential implications for preventing pathological calcification.⁵⁷

Imaging Modalities for Assessing Plaque Change:

Several imaging techniques are employed in research and clinical settings to visualize and quantify atherosclerotic plaques and monitor changes in response to therapy:

• Intravascular Ultrasound (IVUS): Considered a gold standard for quantifying plaque burden in coronary arteries. IVUS provides cross-sectional images from within the artery, allowing measurement of plaque volume (Total Atheroma Volume, TAV) and plaque burden relative to vessel size (Percent Atheroma Volume, PAV).¹³ It can identify calcification but offers limited detail on soft plaque composition.⁵² Advanced techniques like Virtual Histology IVUS (VH-IVUS) provide some characterization of plaque components (fibrous, fibro-fatty, necrotic core, dense calcium).³²
• Optical Coherence Tomography (OCT): An invasive, light-based imaging modality offering very high resolution (~10-20 μm), significantly better than IVUS. OCT excels at visualizing superficial plaque structures, enabling precise measurement of fibrous cap thickness (FCT), detection of macrophage accumulation, characterization of lipid pools, and identification of plaque rupture or erosion.¹⁸ Its limited tissue penetration depth restricts its ability to assess overall plaque volume or deep structures.⁵²
• Near-Infrared Spectroscopy (NIRS): An invasive technique, often combined with IVUS, that specifically quantifies the amount of lipid within the plaque, providing a measure of lipid core burden (e.g., maximum Lipid Core Burden Index in a 4-mm segment, maxLCBI4mm).³⁴
• Coronary Computed Tomography Angiography (CTCA): A non-invasive imaging method using X-rays and contrast dye to visualize the coronary arteries. CTCA can detect stenosis, quantify plaque burden (total, calcified, non-calcified), and identify certain high-risk plaque (HRP) features, such as low-attenuation plaque (LAP, indicative of lipid-rich core), positive remodeling, and spotty calcification.³³ Serial CTCA allows for non-invasive monitoring of plaque changes over time.³³ In the UK, NICE guidelines increasingly advocate for CTCA as a first-line diagnostic tool for patients presenting with stable chest pain.⁸²
• Carotid Intima-Media Thickness (CIMT): A non-invasive B-mode ultrasound measurement of the thickness of the inner two layers (intima and media) of the carotid artery wall. Increased CIMT is considered a marker of subclinical atherosclerosis and is associated with increased cardiovascular risk.¹⁰⁸ However, its added value for risk prediction beyond traditional risk factors is debated, and routine screening with CIMT is not widely recommended in major guidelines, particularly in the UK (NICE NG238 does not recommend it beyond QRISK3) and US.¹¹² Some intervention studies have used CIMT change as a surrogate endpoint.⁴⁷
• Coronary Artery Calcium (CAC) Score: Quantifies the amount of calcified plaque in the coronary arteries using non-contrast CT. CAC score is a strong predictor of future cardiovascular events; a score of zero indicates a very low risk, while higher scores correlate with increased risk. CAC reflects total plaque burden but does not distinguish stable from unstable plaque and is generally not considered useful for monitoring therapeutic response, as calcification may increase during plaque stabilization.³³ NICE NG238 does not recommend routine CAC screening beyond QRISK3 risk assessment.¹¹⁶
• Functional Assessment (FMD, PWV, ABI): Techniques like flow-mediated dilation (FMD) assess endothelial function, pulse wave velocity (PWV) measures arterial stiffness ¹²⁰, and ankle-brachial index (ABI) screens for PAD. These reflect vascular health and predict risk but do not directly image plaque morphology or composition. Their routine use for risk assessment beyond standard scores is not recommended by NICE NG238.¹¹⁶

A significant evolution in the understanding of atherosclerosis treatment goals has occurred. While early research focused heavily on reducing plaque volume (regression) as measured by angiography or IVUS, it became apparent that substantial reductions in clinical events could occur with only modest changes in plaque volume.³⁶ This observation, combined with insights from higher-resolution imaging modalities like OCT and NIRS, shifted the focus towards the importance of plaque stabilization.¹⁷ Stabilization involves favorable compositional changes – such as a reduction in the lipid-rich necrotic core, a decrease in inflammation, and a thickening of the protective fibrous cap – that make the plaque less likely to rupture.¹³ Preventing plaque rupture through stabilization is now recognized as a critical mechanism by which therapies like statins and PCSK9 inhibitors reduce cardiovascular events, potentially being more impactful than achieving large reductions in plaque volume alone.³⁶ The concept of “triple regression” – simultaneously achieving plaque volume reduction, lipid component reduction, and fibrous cap thickening – further integrates these aspects and has been linked to improved clinical outcomes.³⁶

II. Intensive Lipid-Lowering Therapy: Impact on Plaque Burden and Composition

A. The Central Role of LDL-C Reduction

Elevated levels of low-density lipoprotein cholesterol (LDL-C) are unequivocally established as a primary causal factor in the initiation and progression of atherosclerosis.⁷ The process begins when LDL particles infiltrate the arterial intima, become trapped and modified (e.g., oxidized), triggering a maladaptive inflammatory response that drives plaque development.⁷

Consequently, reducing LDL-C levels is the cornerstone of atherosclerosis management and cardiovascular disease (CVD) prevention. A vast body of evidence from numerous randomized controlled trials (RCTs) involving various classes of lipid-lowering therapies (LLTs) – including statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors – consistently supports the “lower is better” hypothesis.⁴⁸ Meta-analyses demonstrate a consistent, approximately 21-22% relative reduction in the risk of major adverse cardiovascular events (MACE) for every 1 mmol/L (approximately 39-40 mg/dL) reduction in LDL-C achieved.²⁴

This strong correlation between LDL-C levels and cardiovascular risk has led major clinical guidelines (e.g., European Society of Cardiology/European Atherosclerosis Society, American College of Cardiology/American Heart Association [ACC/AHA]) to recommend progressively lower LDL-C targets for individuals at higher baseline cardiovascular risk.¹¹⁶ For patients at very high risk (e.g., those with established atherosclerotic CVD), targets of <1.8 mmol/L (70 mg/dL) or even <1.4 mmol/L (55 mg/dL) are often recommended.¹⁴² Some evidence suggests continued benefit even when LDL-C levels are lowered below 1.0 mmol/L (40 mg/dL).³⁶ UK NICE guidelines (NG238) also emphasize achieving specific LDL-C (≤2.0 mmol/L) or non-HDL-C (≤2.6 mmol/L) targets for secondary prevention.¹¹⁴ Non-HDL-C (calculated as Total Cholesterol minus HDL-C) is considered a valuable target as it encompasses cholesterol carried by all potentially atherogenic apoB-containing lipoproteins, including LDL, VLDL, and remnants. NICE recommends a target of >40% reduction in non-HDL-C for primary prevention.¹¹⁴

The mechanisms by which LDL-C lowering leads to plaque regression and stabilization are multifaceted. Reducing circulating LDL-C decreases the concentration gradient driving lipid influx into the arterial wall, thereby limiting further lipid accumulation.¹⁸ This shift in lipid balance favors the efflux of cholesterol from macrophages within the plaque via RCT pathways, contributing to the shrinkage of the lipid core.¹⁸ Furthermore, reducing lipid burden diminishes the inflammatory stimulus within the plaque, leading to decreased recruitment and activation of inflammatory cells and reduced production of detrimental cytokines and enzymes.¹⁷ Serial imaging studies using techniques like IVUS, OCT, and NIRS have directly demonstrated that the magnitude of LDL-C reduction achieved with therapy correlates strongly with the extent of favorable plaque modification, including volume regression and stabilization features.³⁶

While various LLTs possess additional “pleiotropic” effects beyond lipid lowering (e.g., anti-inflammatory effects of statins ⁴⁸), the preponderance of evidence suggests that the degree of LDL-C reduction is the principal determinant of both clinical benefit (event reduction) and the extent of plaque regression/stabilization observed across different drug classes.³⁶ Studies comparing bempedoic acid to statins, for example, found comparable cardiovascular risk reduction when normalized per unit of LDL-C lowering, supporting the primacy of LDL-C reduction itself.¹⁵⁶ This implies that achieving the guideline-recommended LDL-C target through the most appropriate and tolerated therapy is the most critical pharmacological strategy for promoting plaque regression and stabilization.

B. High-Intensity Statins (HIS): Foundational Therapy and Plaque Effects

Statins are the cornerstone of lipid-lowering therapy for both primary and secondary prevention of ASCVD.¹⁴⁸ They function by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This inhibition leads to an upregulation of LDL receptors on hepatocytes, enhancing the clearance of LDL-C from the circulation.⁷ High-intensity statin (HIS) therapy, typically defined as doses expected to lower LDL-C by ≥50% (e.g., atorvastatin 40-80 mg, rosuvastatin 20-40 mg), provides substantial LDL-C reductions ¹⁴⁵ and significantly reduces the risk of cardiovascular events.⁴⁸ Beyond lipid lowering, statins exert pleiotropic effects, including anti-inflammatory actions (e.g., reducing C-reactive protein) and improvements in endothelial function, which may also contribute to their cardiovascular benefits.⁴⁸

Numerous intravascular imaging studies have investigated the effects of statins on coronary atherosclerosis:

• Plaque Progression Slowing and Regression: IVUS trials have consistently demonstrated that HIS therapy is superior to moderate-intensity statin therapy (MIST) or placebo in slowing the progression of coronary atherosclerosis, and can induce plaque regression (reduction in PAV or TAV) in a significant proportion of patients.⁴⁸ Landmark trials like REVERSAL (atorvastatin 80 mg vs. pravastatin 40 mg) showed progression halted with atorvastatin but not pravastatin.⁴⁸ ASTEROID (rosuvastatin 40 mg) and SATURN (rosuvastatin 40 mg vs. atorvastatin 80 mg) demonstrated significant regression of coronary atheroma volume with HIS.⁴⁸ The ESTABLISH trial first showed plaque volume reduction with atorvastatin 20 mg post-ACS.⁴⁸ Meta-analyses confirm that HIS significantly reduces both TAV and PAV.⁶²
• Plaque Compositional Changes: HIS therapy induces favorable changes in plaque composition, indicative of stabilization. IVUS studies have shown reductions in the lipid-rich necrotic core and fibro-fatty components, accompanied by relative increases in fibrous tissue and dense calcium volume.¹³ Higher resolution OCT studies have confirmed that HIS can lead to a significant increase in fibrous cap thickness (FCT), a key feature of plaque stability.⁴⁸ Serial CTCA studies, such as PARADIGM, have shown that statin use is associated with slower progression of overall plaque volume and, importantly, slower progression of non-calcified plaque volume and a reduced incidence of new high-risk plaque features (like LAP), despite potentially faster progression of calcified plaque volume.¹³

The observed plaque modifications with statin therapy provide a biological rationale for the significant reduction in clinical events seen in large outcome trials.⁴⁸

A noteworthy aspect of statin therapy, particularly HIS, is its association with an increase in coronary artery calcification (CAC) volume or density, as observed in both IVUS and CTCA studies.¹³ This might seem paradoxical, given that CAC score is a well-established marker of atherosclerotic burden and cardiovascular risk.¹⁶² However, the nature of calcification may be critical. It is hypothesized that statins promote plaque stabilization by facilitating the transformation of unstable plaque components – reducing the necrotic core, decreasing inflammation, and thickening the fibrous cap – and potentially transforming unstable microcalcifications into denser, more stable calcified areas.¹³ The increase in calcified plaque volume observed with statins in imaging studies may therefore reflect a healing or stabilization process, rather than disease progression. This is supported by CTCA findings showing statins slow non-calcified plaque progression while calcified plaque volume increases.³³ Thus, increased calcification under statin therapy should likely be interpreted within the context of overall plaque changes and clinical benefit, representing a shift towards a more stable plaque phenotype.

C. Ezetimibe: Added Benefit in Plaque Modification

Ezetimibe is a lipid-lowering agent that inhibits the absorption of dietary and biliary cholesterol from the small intestine by selectively blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein transporter located on the brush border of enterocytes.⁵² This reduction in cholesterol delivery to the liver complements the action of statins, leading to further upregulation of LDL receptors and enhanced LDL-C clearance.

As monotherapy, ezetimibe typically lowers LDL-C by approximately 15-20%.¹⁴⁵ When added to ongoing statin therapy, it provides an additional LDL-C reduction of about 15-25% beyond that achieved with the statin alone.⁶³ The clinical benefit of adding ezetimibe to statin therapy was established in the IMPROVE-IT trial, which randomized over 18,000 patients post-ACS to simvastatin plus ezetimibe versus simvastatin plus placebo. The combination therapy achieved a lower median LDL-C (~54 mg/dL vs. ~70 mg/dL) and resulted in a modest but statistically significant reduction in the primary composite endpoint of cardiovascular death, MI, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or stroke over a median follow-up of 6 years.⁵⁰

Several intravascular imaging studies have assessed the impact of adding ezetimibe to statin therapy on coronary plaque morphology:

• Plaque Volume: Meta-analyses of IVUS trials comparing ezetimibe plus statin versus statin monotherapy have generally shown a statistically significant greater reduction in TAV with the combination therapy.⁶⁵ However, the effect on PAV has been less consistent across different meta-analyses, with some showing a significant benefit ⁶⁴ and others not reaching statistical significance.⁶²
• Plaque Composition: Evidence regarding specific compositional changes induced by adding ezetimibe is more limited compared to HIS or PCSK9 inhibitors. One meta-analysis of four IVUS studies using radiofrequency analysis (VH-IVUS) found that ezetimibe plus statin significantly reduced the volume of fibro-fatty plaque compared to statin monotherapy, but observed no significant differences in the changes in fibrous plaque, necrotic core, or dense calcium volumes.⁶³ Studies using higher-resolution modalities like OCT to assess FCT changes specifically with ezetimibe add-on therapy are lacking in meta-analyses.⁶⁶

Clinically, ezetimibe is frequently used as an add-on therapy for patients who do not achieve their LDL-C goals on maximally tolerated statin doses, or as an alternative or combination therapy for patients with statin intolerance.¹¹⁴ NICE guidance supports its use in these scenarios.¹⁷⁷

The available imaging evidence suggests that the beneficial effects of ezetimibe on plaque volume are largely attributable to the additional LDL-C lowering it provides when combined with statins, rather than indicating unique plaque-modifying properties distinct from those driven by LDL-C reduction itself.⁶⁵ While its mechanism complements statins by targeting cholesterol absorption ⁵², and meta-analyses confirm a greater TAV reduction correlating with lower achieved LDL-C ⁶⁵, the data on specific compositional changes like significant FCT thickening or necrotic core reduction are less robust compared to more potent therapies.⁶³ Therefore, ezetimibe’s primary role in plaque modification appears to be facilitating the achievement of lower LDL-C targets than might be possible with statin monotherapy alone.

D. PCSK9 Inhibitors (Alirocumab, Evolocumab): Potent LDL-C Lowering and Plaque Regression/Stabilization

PCSK9 inhibitors represent a major advancement in lipid-lowering therapy. Alirocumab and evolocumab are fully human monoclonal antibodies that target and inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9).⁶⁹ PCSK9 is a protein that binds to LDL receptors on the surface of hepatocytes, targeting them for lysosomal degradation. By inhibiting PCSK9, these antibodies prevent LDL receptor degradation, leading to increased LDL receptor recycling to the cell surface, enhanced LDL-C clearance from the circulation, and consequently, marked reductions in plasma LDL-C levels.⁶⁹

These agents achieve potent LDL-C lowering, typically reducing levels by an additional 50-70% when added to maximally tolerated statin therapy.¹⁴³ Large cardiovascular outcome trials (CVOTs), namely FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab), demonstrated that this substantial LDL-C reduction translates into significant reductions in MACE in high-risk patients with established ASCVD.⁵⁰

The impact of PCSK9 inhibitors on coronary atherosclerosis has been directly assessed in several key intravascular imaging trials:

• Plaque Volume Reduction (IVUS): The GLAGOV trial randomized patients with CAD on optimized statin therapy to evolocumab or placebo. Over approximately 76 weeks, evolocumab resulted in a significantly greater reduction in PAV compared to placebo (-0.95% vs. +0.05%) and TAV (-5.8 mm³ vs. -0.9 mm³).⁶⁹ Atheroma regression (defined as any decrease in PAV from baseline) was observed in 64.3% of patients receiving evolocumab versus 47.3% receiving placebo.³⁴ The ODYSSEY JAPAN IVUS trial showed numerical, though not statistically significant between groups, TAV reduction with alirocumab added to statins.³⁴ A meta-analysis of four studies confirmed that PCSK9 inhibitor therapy leads to significantly greater reductions in both PAV and TAV compared to control therapy in statin-treated patients.⁷⁰
• Plaque Compositional Changes (OCT/NIRS): The PACMAN-AMI trial employed trimodality imaging (IVUS, NIRS, and OCT) in patients post-MI randomized to alirocumab or placebo, on a background of HIS. Alirocumab treatment led to significantly greater PAV reduction (IVUS), a larger decrease in lipid core burden (maxLCBI4mm assessed by NIRS), and a significantly greater increase in minimal FCT (OCT) compared to placebo after 52 weeks.³⁶ Similarly, the HUYGENS trial used OCT post-ACS and found that evolocumab added to statins resulted in a significant increase in FCT and reductions in lipid arc and macrophage index compared to placebo.¹⁷ These findings strongly support the role of PCSK9 inhibitors in promoting plaque stabilization.¹⁷
• Triple Regression: The PACMAN-AMI investigators defined “triple regression” as the simultaneous occurrence of PAV reduction, maxLCBI4mm reduction, and minimal FCT increase in the same patient. This favorable combination of regression and stabilization was achieved significantly more often in the alirocumab group (33.6%) compared to the placebo group (19.5%). Importantly, achieving triple regression was associated with a lower rate of MACE at 1-year follow-up (8.3% vs. 18.2%). Alirocumab treatment and higher baseline lipid content were independent predictors of achieving triple regression.³⁶

PCSK9 inhibitors are indicated for patients at very high cardiovascular risk, including those with clinical ASCVD or heterozygous familial hypercholesterolemia (HeFH), who fail to achieve their LDL-C goals despite maximally tolerated statin therapy, often in combination with ezetimibe.¹⁴⁸ NICE technology appraisals (TA393 for alirocumab, TA394 for evolocumab) provide specific eligibility criteria based on LDL-C thresholds (e.g., ≥3.5 or ≥4.0 mmol/L for secondary prevention depending on risk; ≥5.0 mmol/L for primary prevention HeFH without CVD) and risk categories, contingent on patient access schemes.¹⁸⁶

The imaging data strongly suggest that PCSK9 inhibitors exert robust effects on both plaque volume and composition. Unlike statins, where the effect might be more pronounced on stabilization features (including increased calcification), PCSK9 inhibitors demonstrate significant volumetric regression (PAV and TAV reduction) alongside clear evidence of stabilization (lipid core reduction and FCT thickening).¹⁷ The GLAGOV trial established the volumetric regression ⁶⁹, while PACMAN-AMI and HUYGENS confirmed the compositional stabilization using high-resolution OCT and NIRS.¹⁷ The higher frequency of achieving “triple regression” with alirocumab in PACMAN-AMI underscores this dual benefit.³⁶ This comprehensive effect on both plaque size and vulnerability likely underpins the substantial clinical event reductions observed in the FOURIER and ODYSSEY OUTCOMES trials, even in populations already receiving intensive statin therapy.

E. Bempedoic Acid: Evidence in Statin-Intolerant Patients and Plaque Effects

Bempedoic acid is an oral, once-daily medication representing a newer class of lipid-lowering agents. It inhibits ATP citrate lyase (ACL), an enzyme acting upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway within the liver.⁵² A key characteristic is that bempedoic acid is a prodrug activated by the enzyme very long-chain acyl-CoA synthetase 1 (ACSVL1), which is highly expressed in the liver but has low expression in skeletal muscle. This selective activation potentially minimizes the risk of muscle-related adverse effects commonly associated with statins.²⁴

Clinical trials (CLEAR program) have demonstrated that bempedoic acid, as monotherapy in statin-intolerant patients or as an add-on to moderate-intensity statins, reduces LDL-C by approximately 17-21%.¹⁴² When added to ezetimibe, the LDL-C reduction is around 28% ¹⁹⁸, and the fixed-dose combination of bempedoic acid and ezetimibe lowers LDL-C by about 38%.¹⁹⁸ The large CLEAR Outcomes trial, conducted in over 13,000 statin-intolerant patients at high cardiovascular risk, showed that bempedoic acid reduced the risk of the primary composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke, or coronary revascularization) by 13% relative to placebo over a median follow-up of 40.6 months.¹⁴² Notably, in the pre-specified primary prevention subgroup of CLEAR Outcomes (n=4206), bempedoic acid demonstrated a more pronounced relative risk reduction of approximately 30% for the primary MACE endpoint.¹⁹⁹ Bempedoic acid also reduces levels of high-sensitivity C-reactive protein (hsCRP), an inflammatory marker.¹⁴²

Regarding its effects on atherosclerotic plaque morphology and composition, the evidence is currently limited:

• Coronary Imaging Data: There is a notable absence of large-scale, published clinical trials using established intravascular imaging techniques (IVUS, OCT, NIRS) or serial CTCA to specifically evaluate the impact of bempedoic acid on coronary plaque regression or stabilization.⁵²
• Carotid Ultrasound Study: A small, prospective study involving 22 high-risk patients reported that adding bempedoic acid to existing statin/ezetimibe therapy for 6 months resulted in a statistically significant 7% mean reduction in carotid plaque occlusion percentage, measured by Doppler ultrasound. Plaque reduction was observed in 50% of patients, with a mean reduction of 11% in this responder subgroup.²⁰² However, these findings require validation in larger, more robust studies using standardized coronary imaging endpoints.
• CTCA Case Report: A single published case report described favorable plaque modification (shrinkage of the low-attenuation plaque component) observed on serial CCTA over 20 months in a patient treated with bempedoic acid monotherapy due to statin and ezetimibe intolerance.¹⁰⁰ While interesting, this represents anecdotal evidence.
• Inference Based on LDL-C Lowering: Given the well-established relationship between the magnitude of LDL-C reduction and favorable plaque changes ³⁶, it is biologically plausible that the ~20% LDL-C lowering achieved with bempedoic acid would translate into some degree of plaque stabilization or slowed progression.⁵² The magnitude of this effect would likely be less pronounced than that observed with HIS or PCSK9 inhibitors, corresponding to its more modest LDL-C lowering efficacy.

Clinically, bempedoic acid provides an important option for patients with statin intolerance, either alone or preferably in combination with ezetimibe, and can be considered as an add-on therapy for patients not reaching LDL-C goals on maximally tolerated statins.¹¹⁴ NICE TA694 specifically recommends the fixed-dose combination of bempedoic acid with ezetimibe for primary hypercholesterolemia or mixed dyslipidemia in adults for whom statins are contraindicated or not tolerated, and where ezetimibe alone is insufficient, contingent on a commercial arrangement.²⁰³

The current understanding of bempedoic acid’s impact on plaque is primarily inferred from its established LDL-C lowering efficacy and the positive results of the CLEAR Outcomes trial ¹⁵⁶, rather than direct, robust coronary imaging evidence.⁵² While the small carotid study ²⁰² and the case report ¹⁰⁰ offer preliminary hints, they are insufficient to definitively characterize its effects on coronary plaque morphology and composition relative to other LLTs. Dedicated coronary imaging trials are necessary to elucidate the specific plaque-modifying effects of bempedoic acid. Its demonstrated ability to reduce hsCRP ¹⁴² also suggests potential anti-inflammatory benefits that could contribute to plaque stabilization, but this also requires direct confirmation via plaque imaging.

F. Inclisiran: Novel siRNA Approach and Plaque Imaging Studies

Inclisiran represents a novel therapeutic approach utilizing small interfering RNA (siRNA) technology to lower LDL-C. It targets the messenger RNA (mRNA) encoding for PCSK9 within hepatocytes, leading to the catalytic breakdown of this mRNA and thereby inhibiting the synthesis of the PCSK9 protein.¹⁶ The resulting reduction in circulating PCSK9 levels leads to increased expression of LDL receptors on the liver surface, enhanced LDL-C uptake from the blood, and sustained lowering of plasma LDL-C.²⁰⁸

A key feature of inclisiran is its dosing schedule: after initial doses at baseline and 3 months, it is administered subcutaneously just twice a year (every 6 months).²¹⁰ Clinical trials within the ORION program (including ORION-9, -10, -11, and the ORION-3 open-label extension) have consistently demonstrated that inclisiran, when added to maximally tolerated statin therapy (with or without ezetimibe), provides a potent and sustained LDL-C reduction of approximately 50%.¹⁸⁹ Long-term data from ORION-8 show this efficacy is maintained for up to 6 years of treatment.²⁰⁶ The major cardiovascular outcome trial for inclisiran, ORION-4, is ongoing, with results anticipated in late 2025 or 2026.¹⁴⁸

Evidence regarding the direct effects of inclisiran on coronary plaque morphology and composition is currently emerging:

• Ongoing/Planned Imaging Trials: Dedicated clinical trials designed to evaluate the impact of inclisiran on coronary atherosclerosis using intravascular imaging are underway. For example, NCT06372925 is a Phase IV trial specifically using IVUS and OCT to assess changes in coronary plaque in patients with acute myocardial infarction treated with inclisiran versus control over 12 months.⁷¹
• NIRS Substudy Evidence: A small study (n=36) utilizing NIRS in stable CAD patients investigated the effect of intensive lipid-lowering therapy, including inclisiran added as “bailout” triple therapy for those not at goal on statin/ezetimibe. Over 15 months, significant reductions in plaque lipid content (maxLCBI4mm) were observed, particularly in those achieving LDL-C <1.8 mmol/L.⁷⁹ While involving few patients on inclisiran specifically (n=19 in the triple therapy group), this provides preliminary evidence supporting plaque stabilization.⁸⁰
• Inference Based on LDL-C Lowering: The potent (~50%) and remarkably sustained nature of LDL-C reduction achieved with inclisiran strongly suggests, based on the established link between LDL-C levels and plaque modification, that it will induce significant coronary plaque regression and stabilization.⁷² The magnitude of effect is anticipated to be comparable to that observed with PCSK9 monoclonal antibodies, given the similar degree of LDL-C lowering.⁷² However, direct comparative imaging data are needed for confirmation.

In terms of clinical use, NICE TA733 recommends inclisiran as an option for secondary prevention in adults with a history of specific cardiovascular events (ACS, revascularization, CHD, ischemic stroke, PAD) whose LDL-C remains ≥2.6 mmol/L despite receiving maximally tolerated statins (with or without ezetimibe), or for whom statins are contraindicated or not tolerated.¹⁵⁰ NICE currently does not recommend inclisiran for primary prevention outside of research settings, citing uncertainties in cost-effectiveness and the lack of completed cardiovascular outcome data.²¹⁵ The convenient twice-yearly maintenance dosing may offer advantages in terms of long-term patient adherence compared to therapies requiring more frequent administration.²⁰⁶

Inclisiran holds significant promise for atherosclerosis management due to its novel mechanism and sustained, potent LDL-C lowering.¹⁸⁹ This profile strongly predicts favorable effects on plaque regression and stabilization.⁷² While the preliminary NIRS data are encouraging ⁷⁹, robust confirmation of the extent and nature of these plaque modifications awaits results from larger, dedicated coronary imaging trials like NCT06372925.⁷¹ Until such data become available, the plaque-modifying effects of inclisiran are largely inferred from its profound impact on LDL-C levels, drawing parallels with the established effects of PCSK9 monoclonal antibodies. The completion of the ORION-4 outcome trial will also be crucial in validating the anticipated clinical benefits.¹⁴⁸

Table 1: Summary of Lipid-Lowering Therapy Effects on Coronary Atherosclerotic Plaque

Therapy Class	Typical LDL-C Reduction (Added to Statin)	Key Imaging Trials (Coronary)	Effect on Plaque Volume (PAV/TAV)	Effect on Plaque Composition (Lipid Core / FCT / Calcification)	Key References
High-Intensity Statins (HIS)	Baseline: 40-60%	REVERSAL, SATURN, ASTEROID, ESTABLISH (IVUS); PARADIGM (CTCA)	Slows progression / Induces regression (vs. lower intensity/placebo)	↓ Lipid/Necrotic Core, ↓ Fibro-fatty, ↑ Fibrous Tissue, ↑ FCT (OCT), ↑ Dense Calcium, ↓ High-Risk Plaque Features (CTCA)	13
Ezetimibe (Add-on)	~15-25%	PRECISE-IVUS, others (IVUS meta-analyses)	↓ TAV (significant in meta-analyses); PAV effect less consistent	↓ Fibro-fatty volume (VH-IVUS meta-analysis); Limited data on NC/FCT/Calcium specifically for add-on effect	50
PCSK9 Inhibitors (mAbs)	~50-70%	GLAGOV (IVUS), ODYSSEY J-IVUS; PACMAN-AMI (IVUS/NIRS/OCT), HUYGENS (OCT)	Significant ↓ PAV & TAV (vs. placebo/control)	↓ Lipid Core Burden (NIRS), ↑ Minimal FCT (OCT), ↓ Macrophage Index (OCT); Higher rate of “Triple Regression” (PAV↓, Lipid↓, FCT↑)	17
Bempedoic Acid	~17-21% (mono/add-on); ~38% (combo w/ Ezetimibe)	Limited / Small studies (Carotid US, CTCA case report)	Plausible reduction based on LDL-C lowering; Direct coronary data lacking	Plausible stabilization (↓ hsCRP); Direct coronary data lacking	52
Inclisiran (siRNA)	~50%	Ongoing/Planned (e.g., NCT06372925); Small NIRS substudy	Plausible significant reduction based on LDL-C lowering; Direct coronary data pending	Plausible significant stabilization (↓ Lipid Core – NIRS substudy); Direct coronary data pending	16

Abbreviations: LDL-C: Low-Density Lipoprotein Cholesterol; HIS: High-Intensity Statin; mAbs: Monoclonal Antibodies; siRNA: Small Interfering RNA; IVUS: Intravascular Ultrasound; OCT: Optical Coherence Tomography; NIRS: Near-Infrared Spectroscopy; CTCA: Coronary Computed Tomography Angiography; PAV: Percent Atheroma Volume; TAV: Total Atheroma Volume; FCT: Fibrous Cap Thickness; NC: Necrotic Core; LAP: Low-Attenuation Plaque; hsCRP: High-Sensitivity C-Reactive Protein.

Note: LDL-C reductions are approximate and vary based on baseline levels, specific drug/dose, and background therapy. Plaque effects are based on available evidence from cited sources; “plausible” indicates effects inferred from LDL-C lowering or limited data, awaiting confirmation from larger coronary imaging trials.

III. Lifestyle Interventions: Modifying Risk and Plaque

Lifestyle modifications are fundamental in the prevention and management of atherosclerosis. Key components include adopting heart-healthy dietary patterns, engaging in regular physical activity, smoking cessation, and maintaining a healthy body weight.⁴³

A. Dietary Strategies: Plant-Based, Mediterranean, Low-Fat Diets

Diet is recognized as a critical modifiable risk factor for ASCVD.²²² General guidelines consistently recommend dietary patterns rich in fruits, vegetables, legumes, nuts, whole grains, and fish, while limiting intake of saturated and trans fats, red and processed meats, refined carbohydrates, and sugar-sweetened beverages.⁴³ Specific dietary patterns have been investigated for their potential to influence atherosclerosis progression or regression:

• Plant-Based Diets (PBDs): These diets emphasize consumption of whole, unprocessed plant foods like vegetables, fruits, whole grains, legumes, nuts, and seeds, while minimizing or excluding animal products.¹⁹ Vegan diets represent the strictest form.²²⁸ Proposed mechanisms for benefit include lower intake of saturated fat and dietary cholesterol, higher intake of fiber, antioxidants, and plant polyphenols ¹⁹, reduced production of trimethylamine-N-oxide (TMAO, linked to red meat consumption and atherosclerosis) ¹⁹, lower levels of inflammation (e.g., reduced hsCRP) ¹⁹, reduced oxidative stress ¹⁹, and improvements in endothelial function, lipid profiles, blood pressure, body weight, and glycemic control.¹⁹ The most compelling evidence for plaque regression associated with diet comes from studies involving very low-fat (<10% fat), whole-food PBDs, often combined with other intensive lifestyle changes. The Lifestyle Heart Trial, led by Dr. Dean Ornish, randomized patients with established CAD to an intensive lifestyle program (very low-fat vegetarian diet

Works cited

1. www.mayoclinic.org, accessed April 10, 2025, https://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/symptoms-causes/syc-20350569#:~:text=Atherosclerosis%20is%20the%20buildup%20of,leading%20to%20a%20blood%20clot.
2. Coronary artery disease – Symptoms and causes – Mayo Clinic, accessed April 10, 2025, https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613
3. Arteriosclerosis / atherosclerosis – Symptoms and causes – Mayo Clinic, accessed April 10, 2025, https://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/symptoms-causes/syc-20350569
4. Development of atherosclerosis – Mayo Clinic, accessed April 10, 2025, https://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/multimedia/development-of-atherosclerosis/img-20005848
5. What Is Atherosclerosis? – Nhlbi.Nih.gov, accessed April 10, 2025, https://www.nhlbi.nih.gov/health/atherosclerosis
6. Atherosclerosis: Symptoms, Causes & Treatment – Cleveland Clinic, accessed April 10, 2025, https://my.clevelandclinic.org/health/diseases/16753-atherosclerosis-arterial-disease
7. Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modification treatment – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5355390/
8. Pathophysiology of Atherosclerosis – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/35328769/
9. Atherosclerosis – StatPearls – NCBI Bookshelf, accessed April 10, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507799/
10. Atherosclerosis – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/31420554/
11. Pathobiology of atherosclerosis–a brief review – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/15630673/
12. Pathophysiology of Atherosclerosis – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8954705/
13. ATHEROSCLEROSIS PROGRESSION & REGRESSION: AGENTS TO IMPACT PLAQUE BURDEN, accessed April 10, 2025, https://ccevent.site/wp-content/uploads/2024/09/1105-GMintz-Regression.pdf
14. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6485276/
15. Editorial: Pathophysiology, treatment and rehabilitation of atherosclerosis-related diseases in geriatric population – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10882070/
16. Eradicating Atherosclerotic Events by Targeting Early Subclinical Disease: It Is Time to Retire the Therapeutic Paradigm of Too – American Heart Association Journals, accessed April 10, 2025, https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.123.320065
17. Reversal of Atherosclerotic Plaque Growth and Vulnerability: Effects of Lipid-Modifying and Anti-Inflammatory Therapeutic Agents – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11591594/
18. Plaque Stabilization and Regression, from Mechanisms to Surveillance and Clinical Strategies – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11683705/
19. A Plant-Based Diet, Atherogenesis, and Coronary Artery Disease Prevention – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4315380/
20. The changing landscape of atherosclerosis – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/33883728/
21. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/36009488/
22. Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) – European Cardiology Review (ECR), accessed April 10, 2025, https://www.ecrjournal.com/articles/role-anti-inflammatory-interventions-coronary-artery-disease-understanding-canakinumab
23. Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5753000/
24. Cardiovascular effects of methotrexate in immune‑mediated inflammatory diseases (Review), accessed April 10, 2025, https://www.spandidos-publications.com/10.3892/etm.2018.6992
25. Inflammation in atherosclerosis: pathophysiology and mechanisms – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/39528464/
26. Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6239018/
27. Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11282889/
28. Telomere stabilization by metformin mitigates the progression of atherosclerosis via the AMPK-dependent p-PGC-1α pathway – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11446938/
29. Plaque regression and plaque stabilisation in cardiovascular diseases – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3872716/
30. Carotid artery disease – Symptoms and causes – Mayo Clinic, accessed April 10, 2025, https://www.mayoclinic.org/diseases-conditions/carotid-artery-disease/symptoms-causes/syc-20360519
31. Peripheral artery disease (PAD) – Symptoms and causes – Mayo Clinic, accessed April 10, 2025, https://www.mayoclinic.org/diseases-conditions/peripheral-artery-disease/symptoms-causes/syc-20350557
32. Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management – US Cardiology Review (USC), accessed April 10, 2025, https://www.uscjournal.com/articles/vulnerable-plaque-patients-acute-coronary-syndrome-identification-importance-and?language_content_entity=en
33. Effects of Statins on Coronary Atherosclerotic Plaques: The …, accessed April 10, 2025, https://www.jacc.org/doi/10.1016/j.jcmg.2018.04.015
34. Detection and Stabilisation of Vulnerable Plaques in the Coronary Arteries, accessed April 10, 2025, https://www.japscjournal.com/articles/detection-and-stabilisation-vulnerable-plaques-coronary-arteries
35. Computed Tomography Angiography Identified High-Risk Coronary Plaques: From Diagnosis to Prognosis and Future Management – MDPI, accessed April 10, 2025, https://www.mdpi.com/2075-4418/14/15/1671
36. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy | JACC, accessed April 10, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2023.08.019
37. Early Atherosclerosis Clinic in Minnesota – Overview, accessed April 10, 2025, https://www.mayoclinic.org/departments-centers/early-atherosclerosis-clinic/overview/ovc-20442444
38. Colchicine for Prevention of Major Adverse Cardiovascular Events: A systematic review and meta-analysis of randomized clinical t – medRxiv, accessed April 10, 2025, https://www.medrxiv.org/content/10.1101/2024.12.19.24319310v1.full.pdf
39. Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10646868/
40. Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus – Frontiers, accessed April 9, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1077632/full
41. QRISK3, accessed April 9, 2025, https://qrisk.org/
42. Welcome to the QRISK ® -lifetime cardiovascular risk calculator, accessed April 9, 2025, https://www.qrisk.org/lifetime/
43. Cardiovascular Risk Score (QRISK3) Patient Information Leaflet – Hornchurch Healthcare, accessed April 9, 2025, https://www.hornchurchhealthcare.co.uk/appointmentstest-referrals/tests-investigations/cardiovascular-risk-score-qrisk3-patient-information-leaflet/
44. Cardiovascular Health Risk Assessment – Patient.info, accessed April 9, 2025, https://patient.info/heart-health/cardiovascular-disease-atheroma/cardiovascular-health-risk-assessment
45. Atherosclerotic plaque stabilization and regression: a review of clinical evidence – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/38177454/
46. Nattokinase and Reversal of Atherosclerotic Lesions – Fight Aging!, accessed April 10, 2025, https://www.fightaging.org/archives/2019/01/nattokinase-and-reversal-of-atherosclerotic-lesions/
47. Atherosclerosis: Making a U Turn – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7112505/
48. Stabilization of high-risk plaques – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4960066/
49. Clinical Impact of PCSK9 Inhibitor on Stabilization and Regression of Lipid-Rich Coronary Plaques | PracticeUpdate, accessed April 10, 2025, https://www.practiceupdate.com/content/clinical-impact-of-pcsk9-inhibitor-on-stabilization-and-regression-of-lipid-rich-coronary-plaques/114467
50. The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6629749/
51. Colchicine and plaque: A focus on atherosclerosis imaging – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/38423236/
52. Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9287145/
53. Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/29084546/
54. Colchicine promotes atherosclerotic plaque stability independently of inflammation – bioRxiv, accessed April 10, 2025, https://www.biorxiv.org/content/10.1101/2023.10.03.560632v1.full
55. Reversal of Atherosclerotic Plaque Growth and Vulnerability: Effects of Lipid-Modifying and Anti-Inflammatory Therapeutic Agents – MDPI, accessed April 10, 2025, https://www.mdpi.com/2227-9059/12/11/2435
56. Assessment of Therapeutic Response to Statin Therapy in Patients With Intracranial or Extracranial Carotid Atherosclerosis by Vessel Wall MRI: A Systematic Review and Updated Meta-Analysis, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8578267/
57. Highlighting The Substantial Body Of Evidence Confirming The Importance Of Vitamin K2 As A Cardio-Support Nutrient, And How The Right K2 Makes All The Difference – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7238900/
58. Association of the Inactive Circulating Matrix Gla Protein with Vitamin K Intake, Calcification, Mortality, and Cardiovascular Disease: A Review, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6387246/
59. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5 – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/26176325/
60. Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials – MDPI, accessed April 10, 2025, https://www.mdpi.com/2072-6643/12/10/2909
61. Vitamin K2—a neglected player in cardiovascular health: a narrative review – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8596038/
62. Atherosclerotic coronary plaque regression from lipid-lowering therapies: A Meta-analysis and Meta-regression – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/378878320_Atherosclerotic_coronary_plaque_regression_from_lipid-lowering_therapies_A_Meta-analysis_and_Meta-regression
63. Meta-analysis and trial sequential analysis of ezetimibe for coronary atherosclerotic plaque compositions – Frontiers, accessed April 10, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1166762/full
64. Atherosclerotic coronary plaque regression from lipid-lowering therapies – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10966153/
65. The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/30318063/
66. Effect of ezetimibe–statin combination therapy vs. statin monotherapy on coronary atheroma phenotype and lumen stenosis in patients with coronary artery disease: a meta-analysis and trial sequential analysis – Frontiers, accessed April 10, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1343582/full
67. Identification and treatment of the vulnerable coronary plaque – IMR Press, accessed April 10, 2025, https://www.imrpress.com/journal/RCM/23/1/10.31083/j.rcm2301039/htm
68. Can you reverse plaque buildup? – Marley Drug, accessed April 10, 2025, https://www.marleydrug.com/blog/can-you-reverse-plaque-buildup
69. Impact of PCSK9 Inhibition on Coronary Atheroma Progression: Rationale and Design of GLAGOV (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound) | Request PDF – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/295243614_Impact_of_PCSK9_Inhibition_on_Coronary_Atheroma_Progression_Rationale_and_Design_of_GLAGOV_Global_Assessment_of_Plaque_Regression_with_a_PCSK9_Antibody_as_Measured_by_Intravascular_Ultrasound
70. Effect of PCSK9 antibodies on coronary plaque regression and stabilization derived from intravascular imaging in patients with coronary artery disease: A meta-analysis – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/37666281/
71. Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction – Carebox Connect, accessed April 10, 2025, https://connect.careboxhealth.com/en-US/trial/listing/519075
72. Lipid-lowering Therapy and Coronary Plaque Regression – J-Stage, accessed April 10, 2025, https://www.jstage.jst.go.jp/article/jat/31/11/31_RV22024/_html/-char/en
73. Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11015340/
74. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10067292/
75. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/18817993/
76. The Effects of Statin and Niacin on Plaque Stability, Plaque Regression, Inflammation and Oxidative Stress in Patients With Mild to Moderate Coronary Artery Stenosis – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3242018/
77. (PDF) The Effects of Statin and Niacin on Plaque Stability, Plaque Regression, Inflammation and Oxidative Stress in Patients With Mild to Moderate Coronary Artery Stenosis – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/51920873_The_Effects_of_Statin_and_Niacin_on_Plaque_Stability_Plaque_Regression_Inflammation_and_Oxidative_Stress_in_Patients_With_Mild_to_Moderate_Coronary_Artery_Stenosis
78. Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction | Novartis, accessed April 10, 2025, https://www.novartis.com/clinicaltrials/study/nct06372925
79. Inclisiran-containing low-density lipoprotein cholesterol reduction effectively stabilizes atherosclerotic plaques | European Heart Journal | Oxford Academic, accessed April 10, 2025, https://academic.oup.com/eurheartj/article/45/Supplement_1/ehae666.1440/7837594
80. Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients | European Heart Journal | Oxford Academic, accessed April 10, 2025, https://academic.oup.com/eurheartj/article/44/Supplement_2/ehad655.1313/7392958
81. Implementation of NICE Clinical Guideline 95 for assessment of stable chest pain in a rapid access chest pain clinic reduces the mean number of investigations and cost per patient | Open Heart, accessed April 10, 2025, https://openheart.bmj.com/content/2/1/e000151
82. The 2016 update to NICE CG95 guideline for the investigation of new onset stable chest pain: More innovation, but at a cost? – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/317287954_The_2016_update_to_NICE_CG95_guideline_for_the_investigation_of_new_onset_stable_chest_pain_More_innovation_but_at_a_cost
83. (PDF) Implementation of NICE Clinical Guideline 95 for assessment of stable chest pain in a rapid access chest pain clinic reduces the mean number of investigations and cost per patient – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/272834640_Implementation_of_NICE_Clinical_Guideline_95_for_assessment_of_stable_chest_pain_in_a_rapid_access_chest_pain_clinic_reduces_the_mean_number_of_investigations_and_cost_per_patient
84. CT coronary angiography first prior to rapid access chest pain clinic review: a retrospective feasibility study, accessed April 10, 2025, https://academic.oup.com/bjr/article-pdf/96/1143/20220201/54356906/bjr.20220201.pdf
85. www.nice.org.uk, accessed April 10, 2025, https://www.nice.org.uk/guidance/cg95/resources/recentonset-chest-pain-of-suspected-cardiac-origin-assessment-and-diagnosis-pdf-975751034821
86. The challenge of national CT Coronary Angiography (CTCA) provision in response to NICE CG95 update 2016. BSCI/BSCCT – British Society of Cardiovascular Imaging, accessed April 10, 2025, https://bsci.org.uk/standards-and-guidelines/nice-cg95-update-2016/
87. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Diagnostics Assessment Programme Early value assessment: CaRi-Heart for predic – NICE, accessed April 10, 2025, https://www.nice.org.uk/guidance/hte4/documents/final-scope
88. The 2016 update to NICE CG95 guideline for the investigation of new onset stable chest pain: more innovation, but at a cost?, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6297566/
89. Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis – NICE, accessed April 10, 2025, https://www.nice.org.uk/guidance/cg95
90. The Updated NICE Guidelines: Cardiac CT as the First-Line Test for Coronary Artery Disease – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5368205/
91. Implementation of a modified version of NICE CG95 on chest pain of recent onset: experience in a DGH, accessed April 10, 2025, https://bjcardio.co.uk/2016/11/implementation-of-a-modified-version-of-nice-cg95-on-chest-pain-of-recent-onset-experience-in-a-dgh/
92. NICE CG95 ‘Chest pain of recent onset’, accessed April 10, 2025, https://www.stgeorges.nhs.uk/wp-content/uploads/2018/05/Chest-Pain-by-Kay-Townsend.pdf
93. Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial | Heart, accessed April 10, 2025, https://heart.bmj.com/content/104/3/207
94. New NICE guidelines for the management of stable angina – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5863675/
95. Stable Chest Pain: Are We Investigating a Symptom or Screening for Coronary Disease?, accessed April 10, 2025, https://www.jacc.org/doi/10.1016/j.jcmg.2021.10.011
96. 2013 ESC guidelines on the management of stable coronary artery disease | European Heart Journal | Oxford Academic, accessed April 10, 2025, https://academic.oup.com/eurheartj/article/34/38/2949/442952
97. NICE Guideline update recommends CT angio for stable chest pain, accessed April 10, 2025, https://www.cv-imaging.org/clinical/chest-pain/stable/nice-guideline-update-recommends-ct-angio-for-stable-chest-pain
98. Great Debate: Computed tomography coronary angiography should be the initial diagnostic test in suspected angina – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10327881/
99. (PDF) Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/317987782_Bridging_the_gap_for_lipid_lowering_therapy_plaque_regression_coronary_computed_tomographic_angiography_and_imaging-guided_personalized_medicine
100. Case report: Strong low-density-cholesterol reduction accompanied by shrinkage of low-attenuation coronary plaque during lipid-lowering treatment with bempedoic acid—serial evaluation by coronary computed tomography angiography – Frontiers, accessed April 10, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1203832/full
101. Atherosclerosis Treatment Algorithms for Heart Disease Evaluation – Cleerly, accessed April 10, 2025, https://cleerlyhealth.com/blog/atherosclerosis-treatment-algorithms
102. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography | European Heart Journal | Oxford Academic, accessed April 10, 2025, https://academic.oup.com/eurheartj/article/45/20/1783/7644662
103. Longitudinal assessment of coronary plaque regression related to sodium–glucose cotransporter-2 inhibitor using coronary computed tomography angiography, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11264370/
104. Longitudinal assessment of coronary plaque regression related to sodium-glucose cotransporter-2 inhibitor using coronary computed tomography angiography – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/39039597/
105. Aged Garlic Extract Reduces Low Attenuation Plaque in Coronary Arteries of Patients with Metabolic Syndrome in a Prospective Randomized Double-Blind Study | Request PDF – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/290443073_Aged_Garlic_Extract_Reduces_Low_Attenuation_Plaque_in_Coronary_Arteries_of_Patients_with_Metabolic_Syndrome_in_a_Prospective_Randomized_Double-Blind_Study
106. Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with diabetes: A randomized, double-blind, placebo-controlled study, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6966158/
107. Aged Garlic Extract Reduces Low Attenuation Plaque in Coronary Arteries of Patients with Metabolic Syndrome in a Prospective Randomized Double-Blind Study – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/26764322/
108. Clinical Significance of Carotid Intima-Media Complex and Carotid Plaque Assessment by Ultrasound for the Prediction of Adverse Cardiovascular Events in Primary and Secondary Care Patients, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8538659/
109. Carotid Intima-Media Thickness and Plaque in Cardiovascular Risk Assessment – JACC, accessed April 10, 2025, https://www.jacc.org/doi/10.1016/j.jcmg.2013.11.014
110. Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3557424/
111. Common Carotid Intima-Media Thickness Measurements Do Not Improve Cardiovascular Risk Prediction in Individuals With Elevated Blood Pressure | Hypertension – American Heart Association Journals, accessed April 10, 2025, https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.113.02683
112. Cardiovascular Risk Assessment in Asymptomatic Adults – NEJM Journal Watch, accessed April 10, 2025, https://www.jwatch.org/jc201102090000003/2011/02/09/cardiovascular-risk-assessment-asymptomatic
113. Common Carotid Intima-Media Thickness Measurements Do Not Improve Cardiovascular Risk Prediction in Individuals With Elevated Blood Pressure The USE-IMT Collaboration | Request PDF – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/260682634_Common_Carotid_Intima-Media_Thickness_Measurements_Do_Not_Improve_Cardiovascular_Risk_Prediction_in_Individuals_With_Elevated_Blood_Pressure_The_USE-IMT_Collaboration
114. Cardiovascular disease: risk assessment and reduction, including lipid modification – NICE, accessed April 10, 2025, https://www.nice.org.uk/guidance/ng238
115. Cardiovascular Disease Risk Tests – Medical Clinical Policy Bulletins – Aetna, accessed April 10, 2025, https://www.aetna.com/cpb/medical/data/300_399/0381.html
116. Cardiovascular disease: risk assessment and reduction, including lipid modification | Guidance | NICE, accessed April 10, 2025, https://www.nice.org.uk/guidance/ng238/chapter/Recommendations
117. Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/34372670/
118. Literature update week 03 (2021) [1] Peters EB, Kibbe MR. Nanomaterials to Resolve Atherosclerosis. ACS Biomater Sci Eng 2020; 6 – dach-praevention.eu, accessed April 10, 2025, https://www.dach-praevention.eu/wp-content/uploads/2021/02/pm2021_03_abs.pdf
119. Dietary Intervention to Reverse Carotid Atherosclerosis | Circulation – American Heart Association Journals, accessed April 10, 2025, https://www.ahajournals.org/doi/10.1161/circulationaha.109.879254
120. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force | JACC, accessed April 10, 2025, https://www.jacc.org/doi/10.1016/S0735-1097%2801%2901746-6
121. Expert consensus document on arterial stiffness: methodological issues and clinical applications | European Heart Journal | Oxford Academic, accessed April 10, 2025, https://academic.oup.com/eurheartj/article-abstract/27/21/2588/2887386?redirectedFrom=fulltext
122. Aortic-Femoral Stiffness Gradient and Cardiovascular Risk in Older Adults | Hypertension, accessed April 10, 2025, https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.124.23392
123. Arterial stiffness tested by pulse wave velocity and augmentation index for cardiovascular risk stratification in antiphospholipid syndrome | Rheumatology | Oxford Academic, accessed April 10, 2025, https://academic.oup.com/rheumatology/article/63/4/1030/7193000
124. Cardiovascular disease prevention | Guidance – NICE, accessed April 10, 2025, https://www.nice.org.uk/guidance/ph25
125. The validity of carotid-femoral pulse wave velocity in the seated posture as an index of central arterial stiffness – American Journal of Physiology, accessed April 10, 2025, https://journals.physiology.org/doi/full/10.1152/ajpregu.00073.2024
126. Arterial stiffness and cardiovascular events: The Framingham Heart Study – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2836717/
127. Arterial Stiffness – PhysioWave, accessed April 10, 2025, https://www.physiowave.com/company/cv-risk/
128. Arterial stiffness measured by pulse wave velocity correlated with cognitive decline in hypertensive individuals: a systematic review – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11481605/
129. 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices | Hypertension – American Heart Association Journals, accessed April 10, 2025, https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.21618
130. Pulse wave velocity: a marker of arterial stiffness and its applicability in clinical practice, accessed April 10, 2025, https://revportcardiol.org/en-pulse-wave-velocity-marker-arterial-articulo-S2174204911700125
131. Impact of Cardiovascular Factors on Pulse Wave Velocity and Total Vascular Resistance in Different Age Group Patients with Cardiovascular Disorders – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6635425/
132. Pulse Wave Velocity in Atherosclerosis – Frontiers, accessed April 10, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2019.00041/full
133. Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born? – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/38136567/
134. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6884628/
135. Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review, accessed April 10, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2021.10.035
136. Metformin Directly Binds to MMP-9 to Improve Plaque Stability – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/36826550/
137. Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE-/- mice – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/33915432/
138. Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A systematic review and meta-analysis – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/36523368/
139. Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/32140929/
140. Meta-Analysis Comparing the Effect of Combined Omega-3 + Statin Therapy Versus Statin Therapy Alone on Coronary Artery Plaques – PubMed, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/34049675/
141. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice, accessed April 10, 2025, https://pubmed.ncbi.nlm.nih.gov/25425200/
142. Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10219398/
143. The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4719137/
144. Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors | ECR Journal, accessed April 9, 2025, https://www.ecrjournal.com/articles/management-severe-dyslipidaemia-role-pcsk9-inhibitors?language_content_entity=en
145. Ezetimibe – An Overview of its Low-density Lipoprotein Cholesterol Lowering Efficacy, accessed April 9, 2025, https://www.ecrjournal.com/articles/ezetimibe-overview-its-low-density-lipoprotein-cholesterol-lowering-efficacy?language_content_entity=en
146. Ezetimibe: The Lower the LDL-C, the Better (Even for Total Cardiovascular Events), accessed April 9, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2016/03/09/06/50/Ezetimibe-The-Lower-the-LDLC-the-Better
147. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024, accessed April 10, 2025, https://diabetesjournals.org/care/article/47/Supplement_1/S179/153957/10-Cardiovascular-Disease-and-Risk-Management
148. Cardiovascular disease — risk assessment and reduction: NICE 2023 update for GPs, accessed April 9, 2025, https://bjgp.org/content/74/748/523
149. Q&A: Lipid management – Part 2: Use of statins – DiabetesontheNet, accessed April 9, 2025, https://diabetesonthenet.com/diabetes-primary-care/qa-lipid-management-part-2-use-of-statins/
150. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD, accessed April 9, 2025, https://www.nottsapc.nhs.uk/media/0aod5fib/final-hyperlipidaemia-guidelines.pdf
151. Lipid Management for the Primary and Secondary Prevention of Cardiovascular Disease – Kidney Research UK, accessed April 9, 2025, https://www.kidneyresearchuk.org/wp-content/uploads/2025/02/Lipids_Primary_Care_Hack_v8_Feb_25.pdf
152. Lipids module 4: treatment of dyslipidaemia – The British Journal of Cardiology, accessed April 9, 2025, https://bjcardio.co.uk/2024/06/lipids-module-4-treatment-of-dyslipidaemia-5/
153. Cardiovascular disease: risk assessment and reduction, including lipid modification | NICE, accessed April 10, 2025, https://www.nice.org.uk/guidance/ng238/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-66143902851781
154. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein | Circulation, accessed April 9, 2025, https://www.ahajournals.org/doi/10.1161/01.CIR.100.3.230
155. Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes | Arteriosclerosis, Thrombosis, and Vascular Biology – American Heart Association Journals, accessed April 9, 2025, https://www.ahajournals.org/doi/10.1161/01.atv.0000163840.63685.0c
156. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin …, accessed April 9, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2024.04.048
157. Bempedoic acid has similar CV benefits as statins when normalized …, accessed April 9, 2025, https://pace-cme.org/news/bempedoic-acid-has-similar-cv-benefits-statins-when-normalized-degree-ldl-c-lowering/2468192/
158. Study Shows Bempedoic Acid Comparable to Statins in … – HCPLive, accessed April 9, 2025, https://www.hcplive.com/view/study-shows-bempedoic-acid-comparable-to-statins-in-cardiovascular-protection
159. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin …, accessed April 9, 2025, https://pubmed.ncbi.nlm.nih.gov/38960508/
160. Cardiovascular risk assessment and lipid modification: NICE guideline – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4484941/
161. Q&A: Lipid management – Part 2: Use of statins | DiabetesontheNet, accessed April 9, 2025, https://diabetesonthenet.com/wp-content/uploads/91.-QA-Lipids-pt2-statins.pdf
162. Assessing Cardiovascular Risk with Coronary Artery Calcium and Carotid Intima-Media Thickness in Patients with Negative Stress Echocardiography, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11429111/
163. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines – ResearchGate, accessed April 10, 2025, https://www.researchgate.net/publication/49629583_2010_ACCFAHA_Guideline_for_Assessment_of_Cardiovascular_Risk_in_Asymptomatic_Adults_A_Report_of_the_American_College_of_Cardiology_FoundationAmerican_Heart_Association_Task_Force_on_Practice_Guideline
164. Coronary artery calcium (CAC) score for cardiovascular risk stratification in a Thai clinical cohort, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10788496/
165. Coronary Artery Calcium Scoring for Prevention of Cardiovascular Disease – AAFP, accessed April 10, 2025, https://www.aafp.org/pubs/afp/issues/2022/0700/diagnostic-tests-coronary-artery-calcium-scoring.html
166. Major Global Coronary Artery Calcium Guidelines | JACC: Cardiovascular Imaging, accessed April 10, 2025, https://www.jacc.org/doi/10.1016/j.jcmg.2022.06.018
167. Major Global Coronary Artery Calcium Guidelines: Key Points, accessed April 10, 2025, https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2022/10/04/19/19/Major-Global-Coronary-Artery
168. Role of Coronary Artery Calcium for Stratifying Cardiovascular Risk in Adults With Hypertension – American Heart Association Journals, accessed April 10, 2025, https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.118.12266
169. Coronary artery calcium in primary prevention – RACGP, accessed April 10, 2025, https://www1.racgp.org.au/ajgp/2020/august/coronary-artery-calcium-in-primary-prevention
170. Coronary artery calcium score: current status – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5487233/
171. Coronary artery calcium score (CACS) – Patient.info, accessed April 10, 2025, https://patient.info/doctor/coronary-artery-calcium-score
172. Coronary Artery Calcification (Remedy BNSSG ICB), accessed April 10, 2025, https://remedy.bnssg.icb.nhs.uk/adults/cardiology/coronary-artery-calcification/
173. Bempedoic acid (monotherapy) or bempedoic acid in combination with ezetimibe for primary hypercholesterolaemia or mixed dyslipidaemia – NIHR Innovation Observatory, accessed April 9, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/12682-Bempedoic-acid-with-or-without-ezetimibe-for-hypercholesterolaemia-V1.0-SEP2018-NONCONF.pdf
174. Perspectives in Cholesterol-Lowering Therapy – American Heart Association Journals, accessed April 9, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.0000072345.98581.24
175. Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11685754/
176. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor, accessed April 9, 2025, https://academic.oup.com/eurheartjsupp/article-pdf/3/suppl_E/E11/9795884/E11.pdf
177. www.nice.org.uk, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta385/documents/final-appraisal-determination-document
178. Statin Intolerance Pathway, accessed April 9, 2025, https://www.nottsapc.nhs.uk/media/1702/statin-intolerance-pathway.pdf
179. South West London Integrated Care System Lipid Management Guidance: Adult Medicines Optimisation pathways, accessed April 9, 2025, https://swlimo.southwestlondon.icb.nhs.uk/wp-content/uploads/SWL-Lipid-management-guidelines-for-adults-V2.0.pdf?UNLID=1040849582025215165327
180. NPC Archive Item: Ezetimibe in hypercholesterolaemia: NICE guidance, accessed April 9, 2025, https://www.centreformedicinesoptimisation.co.uk/ezetimibe%E2%96%BC-in-hypercholesterolaemia-nice-guidance/
181. Ezetimibe for treating primary heterozygous- familial and non-familial hypercholesterolaemia | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta385/resources/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia-pdf-82602851386309
182. Referral criteria – intolerant to statins (statin intolerance) – GPnotebook, accessed April 9, 2025, https://gpnotebook.com/en-GB/pages/cardiovascular-medicine/referral-criteria-intolerant-to-statins-statin-intolerance
183. (PDF) Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy – ResearchGate, accessed April 9, 2025, https://www.researchgate.net/publication/352961436_Cost-Effectiveness_Analysis_of_Alirocumab_in_High_Cardiovascular-Risk_Patients_in_Italy
184. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance: The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab | JACC, accessed April 9, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2014.03.019
185. Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy | Povero | Farmeconomia. Health economics and therapeutic pathways, accessed April 9, 2025, https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1499/1879
186. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta393/resources/alirocumab-for-treatingprimary-hypercholesterolaemia-and-mixeddyslipidaemia-pdf-82602908493253
187. NICE TA implementation guidance – Alirocumab and evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia – East Kent Prescribing Formulary, accessed April 9, 2025, https://www.eastkentformulary.nhs.uk/media/1138/ekpg-recommendation-evolocumab-and-alirocumab-for-hypercholesterolaemia.pdf
188. 3 Evidence | Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | Guidance | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta393/chapter/3-Evidence
189. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial – JACC Journals, accessed April 9, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499
190. Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain – Revista Española de Cardiología, accessed April 9, 2025, https://www.revespcardiol.org/en-cost-effectiveness-and-budget-impact-of–articulo-S1885585718301877
191. Cardiovascular disease: risk assessment and reduction, including lipid modification (2014) NICE guideline CG181 – Appendix B – NCBI, accessed April 9, 2025, https://www.ncbi.nlm.nih.gov/books/NBK550918/bin/nicecg181surv_AppendixB.pdf
192. NICE and SMC Guidance Praluent® (alirocumab) – Sanofi campus, accessed April 9, 2025, https://pro.campus.sanofi/uk/dyslipidaemia/articles/nice-and-smc-guidance-praluent
193. 4 Consideration of the evidence | Evolocumab for treating primary …, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta394/chapter/4-consideration-of-the-evidence
194. ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6047410/
195. Clinical Utilization and Performance of Bempedoic Acid in an Italian Real-World Setting: Insight from Campania Region, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11943254/
196. Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside – MDPI, accessed April 10, 2025, https://www.mdpi.com/1422-0067/24/9/8062
197. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance | Journal of the American Heart Association, accessed April 9, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.118.011662
198. Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention – PubMed Central, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10900064/
199. Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention | tctmd.com, accessed April 9, 2025, https://www.tctmd.com/news/big-reductions-ascvd-events-bempedoic-acid-primary-prevention
200. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs | Request PDF, accessed April 9, 2025, https://www.researchgate.net/publication/381904644_Comparative_Cardiovascular_Benefits_of_Bempedoic_Acid_and_Statin_Drugs
201. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients – PubMed, accessed April 9, 2025, https://pubmed.ncbi.nlm.nih.gov/37354546/
202. CAROTID PLAQUES TREATED WITH BEMBEDOIC ACID: A 7% OF REDUCTION IN 6 MONTHS – Oxford Academic, accessed April 10, 2025, https://academic.oup.com/eurheartjsupp/article/26/Supplement_2/ii114/7674354
203. www.nice.org.uk, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta694/documents/final-appraisal-determination-document
204. Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid – Business Wire, accessed April 9, 2025, https://www.businesswire.com/news/home/20240926678909/en/Final-Real-World-Results-from-MILOS-German-Cohort-Demonstrate-Strong-Increase-in-LDL-C-Goal-Achievement-With-Addition-of-Bempedoic-Acid
205. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta694/resources/bempedoic-acid-with-ezetimibe-for-treating-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-pdf-82609440519877
206. Briefing note: The role of inclisiran in lipid management – NHS England, accessed April 9, 2025, https://www.england.nhs.uk/long-read/briefing-note-the-role-of-inclisiran-in-lipid-management/
207. Leqvio 284 mg solution for injection in pre filled syringe – Summary of Product Characteristics (SmPC) – (emc) | 12039, accessed April 9, 2025, https://www.medicines.org.uk/emc/product/12039/smpc
208. Inclisiran Information for Healthcare Professionals Quick Reference Guide 03.07.23.docx, accessed April 9, 2025, https://surreyccg.res-systems.net/PADFormularyV1/Content/Documents/2/Final%20Inclisiran%20Information%20for%20Healthcare%20Professionals%20Quick%20Reference%20Guide%2003.07.23%20(007)%20(1).docx
209. Leqvio | European Medicines Agency (EMA), accessed April 9, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
210. Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders – PubMed Central, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11865805/
211. New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender, accessed April 9, 2025, https://www.novartis.com/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender
212. Efficacy & Clinical Trials | LEQVIO® (inclisiran) | HCP, accessed April 9, 2025, https://www.leqviohcp.com/efficacy
213. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials, accessed April 9, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2023.10.007
214. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial | Cardiovascular Research | Oxford Academic, accessed April 9, 2025, https://academic.oup.com/cardiovascres/article/120/12/1400/7675310
215. 3 Committee discussion | Inclisiran for treating primary … – NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta733/chapter/3-Committee-discussion
216. Amber Guidance for Inclisiran for treating Primary Hypercholesterolaemia or Mixed Dyslipidaemia, accessed April 9, 2025, https://www.northernlincolnshireapc.nhs.uk/wp-content/uploads/2022/10/Amber-1-Inclisiran-guideline-10.22.pdf
217. Leqvio, INN-inclisiran, accessed April 9, 2025, https://www.medicines.org.uk/emc/files/pil.12039.pdf
218. Prescribing Support Guide Inclisiran (Leqvio®) for treating primary hypercholesterolaemia or mixed dyslipidaemia, accessed April 9, 2025, https://www.hweclinicalguidance.nhs.uk/all-clinical-areas-documents/download?cid=2497&checksum=d9fc0cdb67638d50f411432d0d41d0ba
219. Inclisiran Side Effects: Common, Severe, Long Term – Drugs.com, accessed April 9, 2025, https://www.drugs.com/sfx/inclisiran-side-effects.html
220. Cardiovascular Risk Assessment | Doctor – Patient.info, accessed April 9, 2025, https://patient.info/doctor/cardiovascular-risk-assessment
221. The Heart of the Matter (Part 2): NICE Guidelines on CVD risk reduction and Lipid Management – YouTube, accessed April 9, 2025, https://www.youtube.com/watch?v=QyN3toBGCNU
222. Effect of a 15-Week Whole Foods, Plant-Based Diet, Physical Activity, and Stress Management Intervention on Cardiometabolic Risk Factors in a Population of US Veterans – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11562218/
223. Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11295104/
224. The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels – NCBI, accessed April 10, 2025, https://www.ncbi.nlm.nih.gov/books/NBK570127/
225. A Heart-Healthy Diet for Cardiovascular Disease Prevention: Where Are We Now? – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10128075/
226. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7734661/
227. Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8315554/
228. Anti‐Inflammatory Effects of a Vegan Diet Versus the American Heart Association–Recommended Diet in Coronary Artery Disease Trial – PMC – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6405545/
229. A Look at Plant-Based Diets – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8210981/
230. Plant-Based Nutrition: Exploring Health Benefits for Atherosclerosis, Chronic Diseases, and Metabolic Syndrome—A Comprehensive Review – PubMed Central, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10386413/

A plant-based diet and heart failure: case report and literature review – PMC, accessed April 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5466944/